SEC Form 4 · accession 0001209191-18-058692
Arcus Biosciences, Inc. · RCUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Juan C. Jaen
Officer — President · Director
Period of report
Nov 13, 2018
Accepted (ET)
Nov 15, 2018 · 1:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001724521
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 13, 2018 | P | 10,000 | $11.8039 | A | 2,754,240 | I | By Trust |
| Common Stock | holding | — | — | — | 189,393 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.64 to $12.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.